See: Is Big Media Ignoring Fact Checkers And Spreading Disinformation?

Written By BlabberBuzz | Tuesday, 12 October 2021 09:30

Blue checkmarks in the sphere of establishment media Twitter discourse today chose to say COVID antibodies are only a cash grab by "Big Pharma," and that the COVID vaccine by the likes of Pfizer and Moderna are generous measures not meant for making money off of.

It started when Allen West made a Twitter thread about his and his wife's experiences getting monoclonal antibody treatments for COVID at an emergency room location in Medical City, Plano, Texas.

The results as described by Mr. West were positive, and he thinks monoclonal antibody infusion therapy is a viable alternative for fighting COVID as we advance.

NO SCIENCE TO CALIFORNIA'S CRACKDOWN ON GAS

NO SCIENCE TO CALIFORNIA'S CRACKDOWN ON GAS

Chris Hayes maligns the monoclonal antibody treatment as something that "Big Pharma" sells straight to patients, asking for $2000 in return.

Christina Pushaw corrected him by pointing out to Hayes that "vaccinated people need monoclonal antibodies too."

WATCH: CHICAGO'S EVIL MAYOR VILIFIES COPS ON CAMERA

WATCH: CHICAGO'S EVIL MAYOR VILIFIES COPS ON CAMERA

In addition, both the COVID vaccine and antibodies are "free" to patients while simultaneously costing "the federal government (taxpayers) billions, but no one has to pay 2k a pop for mAb treatment in Florida."

Hayes isn't the only one. People like Kevin Kruse and Max Kennerly played into the idea that Pfizer themselves aren't a "Big Pharma" company.

RAND PAUL INVITES MANCHIN TO DEFECT FROM THE DARK SIDE

RAND PAUL INVITES MANCHIN TO DEFECT FROM THE DARK SIDE

Again, the spokesperson for Florida Governor DeSantis states outright that "both mAb and vaccine are free to patients."

Pushaw doubled down after the fact, reiterating "40-60 percent of patients at the MAB treatment sites in Florida (depending on location) were vaccinated and had breakthrough cases."

FACT: SUPPLY CHAIN CRISIS HURTING MOST AMERICANS

FACT: SUPPLY CHAIN CRISIS HURTING MOST AMERICANS

It was late last month that Florida Governor DeSantis triumphantly got a supply of COVID antibody doses, Sotrovimab, directly from the manufacturer.

The Biden administration had previously chosen to buy up Regeneron's antibodies in a last-ditch attempt to control the supply at a federal level.

WATCH: DEM GUBERNATORIAL CANDIDATE WALKS OUT OF INTERVIEW AFTER TOUGH QUESTIONS

WATCH: DEM GUBERNATORIAL CANDIDATE WALKS OUT OF INTERVIEW AFTER TOUGH QUESTIONS

Meanwhile, Trident Medical Center announced that 97% of patients battling COVID-19 could recover at home after getting monoclonal antibody infusion therapy.

The center announced that over 1,200 Lowcountry and Upstate patients who were newly diagnosed with the coronavirus got the treatment to reduce the virus's symptoms.

"Hospital officials say the treatment accomplished its intended purpose - help reduce COVID-related hospitalizations," Trident officials announced.

The hospital has created its monoclonal antibody clinic with the treatment available for patients at more locations in the Lowcountry.

Bamlanivimab, a monoclonal antibody infusion therapy, is a type of treatment for non-hospitalized patients with mild or moderate cases of COVID-19 aimed to prevent patients from becoming hospitalized patients.

The therapy for emergency-use authorization from the U.S. Food and Drug Administration on Nov. 9, and they say the treatment has a 98% effective rate in preventing hospitalizations.

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's

Start your own discussion or comment on someone else's